article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Congress passed the RTT Act in 2018 to give qualifying patients access to investigational drugs outside of a clinical trial setting. Psilocybin successfully completed an FDA-approved Phase 1 clinical trial in 2019, and two companies, COMPASS Pathways and Usona, both currently have Phase 2 trials ongoing.

DEA 52
article thumbnail

Dr. Andrew Weil on Cannabis and Integrative Medicine

Project CBD

He is the author of several bestselling books, including Spontaneous Healing (1995), Eating Well for Optimum Health (2000), and Healthy Aging (2007). We rate levels of evidence, and a high level may be a controlled randomized clinical trial (RCT), but there are also observational studies. Cannabis is such an interesting plant.

Medicine 301
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CBD, THC, AND CANCER

Weedistry

A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies.

THC 40
article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. ElleVet products are now the only hemp CBD/CBDA products proven both effective and safe for dogs and cats. This study proved the efficacy of ElleVet’s hemp CBD/CBDA. Joseph Wakshlag, DVM, Ph.D.,

Safety 45
article thumbnail

Israel’s Tikun Olam Making Moves in the U.S. and Canada

Freedom Leaf

Tikun Olam , which was founded in 2007, controls nearly 40% of the Israeli medical-marijuana market. We’re also continuing to do some other clinical trials in Israel, specifically with our strains.” We’ve been able to do this for 15 years, which provided us with the ability to do more clinical trials and research.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. JPET 322:236–242, 2007.